Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16613941 | 0.82 | PDE4D (0.34) | PDE4D | |
| SCHEMBL10086799 | 0.75 | PDE4D (0.45) | ALDH1A1LMNAPDE4DTSHR | |
| SCHEMBL18023438 | 0.70 | ALDH1A1 (0.30) | ALDH1A1LMNA | |
| SCHEMBL21361679 | 0.65 | ALDH1A1 (0.42) | ALDH1A1LMNAFAAHMGLL | |
| SCHEMBL18022065 | 0.65 | — | — | |
| SCHEMBL296010 | 0.63 | NAAA (0.58) | ALDH1A1LMNAFAAHMGLL | |
| SCHEMBL18022096 | 0.63 | TBXA2R (0.53) | ALDH1A1LMNAPDE4DTSHR | |
| SCHEMBL1052220 | 0.62 | — | — | |
| SCHEMBL514869 | 0.62 | — | — | |
| SCHEMBL2281311 | 0.62 | BCHE (0.41) | ALDH1A1LMNAFAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PATHEON API SERVICES INC. | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PTGES, PTGIS, PTGES2 | ALDH1A1 1734/4885LMNA 3324/4885FAAH 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.